ASX Announcements / Media releases
The purpose of this webpage and subsequent document is to provide information to existing and prospective investors, and potential commercial partners, about the current status of BCAL’s research and development. It is not intended to promote the use or supply of any therapeutic goods.
15 Nov 2022
Shareholder Newsletter. Read more
25 October 2022
Establishment of Development & Clinical Services Laboratory. Read more
16 Jan 2023
ASX Announcement. Read more
24 Apr 2023
ASX Announcement. Read more
16 May 2023
ASX Announcement. Read more
28 June 2022
BCAL Enters US Product Development Agreement with Precion. Read more
1 June 2022
BCAL Presentation Accepted for 2022 ASCO Annual Meeting. Read more
12 May 2022
BCAL Files Foundational Patent Application. Read more
24 Mar 2022
Shareholder Newsletter. Read more
8 Feb 2022
7 February Announcement - Additional Information. Read more
7 Feb 2022
Recent Analysis Significantly Improves Commercial Prospects. Read more
11 Jan 2022
Dr John Hurrell Appointed Chief Executive Officer. Read more
3 Nov 2021
Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test. Read more
21 Oct 2021
Notice of Annual General Meeting and Explanatory Statement. Read more
3 Sep 2021
Australian Clinical Studies Launched. Read more
17 Aug 2021
Market Update. Read more
22 July 2021
Becoming a substantial holder. Read more
21 July 2021
BCAL Diagnostics to list after raising $10m in IPO. Read more